EVCA, SFBE, HIHO, PIP, ENTI, CBIS
Our Stocks to Watch today include FutureWorld Energy Inc. (OTC: FWDG), Tactical Air Defense Services Inc. (OTCBB: TADF), Evarco Inc. (OTCBB: EVCA), Sino Fibre Communications Inc. (OTCBB: SFBE), Highway Holdings Ltd. (Nasdaq: HIHO), PharmAthene Inc. (NYSE Amex: PIP), Encounter Technologies Inc. (OTC: ENTI) and Cannabis Science Inc. (OTCBB: CBIS).
FUTUREWORLD ENERGY INCORPORATED (OTC: FWDG)
"Up 50.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/FWDG.php
Company Profile: http://www.otcpicks.com/FutureWorld-Energy.htm
FutureWorld Energy, Inc., a Delaware corporation, is a U.S. Diversified Energy Holding Company, listed on the Over the Counter exchange, which was formed to capitalize on the burgeoning markets in renewable and alternative energy technologies globally. FutureWorld Energy, together with its subsidiaries, focuses on the identification, acquisition, development, and commercialization of renewable and alternative energy technologies globally. Through established relationships with universities, research centers and government agencies, we strive to identify technologies on the leading edge of innovation that would contribute immensely to the global energy needs while protecting the future for our children and theirs.
October 12 - FutureWorld Energy Launches New Branding and Marketing Campaign
Futureworld Energy, Inc. (OTC: FWDG), a global provider of alternative, renewable and clean energy technologies, announced the company has retained the services of Tampa, Florida-based Vivid Infusion to rebrand the FutureWorld Energy image through integrated marketing campaigns and contemporary digital communications solutions.
"FutureWorld Energy is pleased to retain Vivid Infusion to rebrand our organization as we focus on growing the business and becoming the leading alternative energy solutions provider," states Michael Shoaff, COO, FutureWorld Energy, Inc. "We are extremely excited about the future growth opportunities for FutureWorld Energy and will use our rebranding campaigns to educate the public about alternative technology that makes both environmental and economic sense."
Key elements of the FutureWorld rebranding campaigns include a contemporary, informational and interactive website, vibrant new logo and color scheme.
"Vivid Infusion is honored to be chosen for the global rebranding of FutureWorld," said Thomas Nagy, President of Vivid Infusion. "FutureWorld has the right product mix that will set itself apart from the rest. On behalf of our management team, we look forward to proudly developing the FutureWorld brand identity to ultimately be recognized as the leader in secure global utility communications."
TACTICAL AIR DEFENSE SERVICES INCORPORATED (OTCBB: TADF)
Detailed Quote: http://www.otcpicks.com/quotes/TADF.php
Company Profile: http://otcpicks.com/Tactical-Air-Defense.htm
Tac-Air is a privately-held Aerospace/Defense Services contractor founded by a group of former Navy, Marine, and Air Force Weapon's School Instructors, which has won and successfully executed multiple Aerospace/Defense contracts by divisions of the U.S. Department of Defense.
October 13 - Tactical Air Defense Services Receives Financing Commitment for Aircraft Asset Purchase
Tactical Air Defense Services, Inc. (OTCBB: TADF), an Aerospace/Defense Services contractor that offers tactical aviation services, aerial refueling, aircraft maintenance, disaster relief services, and other Aerospace/Defense services to the United States and Foreign militaries and agencies, is pleased to announce that it has received a $5,000,000 financing commitment from Crown Pacific Advisors, LLC to fund the purchase of military aircraft and related assets.
Pursuant to an asset purchase agreement, Tactical Air Defense Services, Inc. ("TADF") intends to use the $5,000,000 to purchase certain military fighter jets, related parts, and jet engines to capture new tactical aviation service contracts and maintenance service contracts, with both the U.S. Department of Defense and foreign militaries.
TADF management believes that when fully operational and under contract, the aircraft may add between $9,000,000 and $13,500,000 in the aggregate per year to its top-line revenue.
In addition, TADF anticipates that the aircraft, related parts, and jet engines may add approximately $24 million of assets to its balance sheet, as well as provide additional cash-flows to the Company from sales of surplus spare parts and jet engines.
TADF management believes that it may begin to generate cash-flows from contract revenues and asset sales no later than the first quarter of 2011, although it is possible that some of the aircraft will be operational and generating revenue under contract before year-end 2010.
The military aircraft that TADF intends to purchase are cost effective, low-maintenance, and extremely versatile fighter jets that can be used to provide a tactical support role as an air to ground close air support training platform or dissimilar air combat training aircraft , in support of tactical aviation contracts.
Crown Pacific Advisors, LLC is a Merchant Bank specializing in the financing of aviation assets. Crown Pacific Advisors is not a shareholder of TADF.
Alexis C. Korybut, Chief Executive Officer of TADF, stated, "We believe the $5,000,000 financing commitment from Crown Pacific for the purchase of these aircraft and related assets is a watershed event for TADF. The acquisition of these fighter jets will enable TADF to bid on larger and more profitable tactical aviation contracts and aircraft maintenance contracts, and the sale of any surplus spare parts and engines may provide a significant source of income to TADF for years to come, in addition to materially increasing the assets on our balance sheet."
STOCKS TO WATCH
EVCARCO INCORPORATED (OTC: EVCA)
"Up 75.88% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/EVCA.php
Evarco Inc. is the Future Driven® automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. Evarco is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles. Evarco has developed a dealer network allowing growth into most US States by 2012.
September 23 - Evarco Releases Highly Anticipated Next Generation Tazzari-Zero; Latest Innovations and 2012 Tazzari Roadster
The Jewel of Evarco's Line Up Showcases Its Latest Advancements and Unveils the 2012 Tazzari Zero Spider
Evarco (OTCBB: EVCA) presents to the shareholders of Evarco the latest update from its Italian manufacturer Tazzari.
Tazzari Group Italy reports that over 6 months have passed since Zero was launched. While a discerning public admires its technological features, ecological concept, its design and the performance of this all-electric vehicle built using cutting-edge techniques, the Tazzari team is busy planning and defining the vehicle's coming innovations.
What's in store for 2011:
Planned for spring next year there will be a number of innovations that are currently at an advanced stage of development.
These include a driver control panel with touch-screen technology. Part of the dashboard, the new control panel will give the driver easy, finger-tip control over a range of vehicle functions. Its design is essential and ultra-modern and this instrument represents a major innovation in the automotive sector, bringing it closer to that of latest-generation communication devices such as the iPod.
Externally, there will be a number of new optional features such as LED lights and front fog lamps. As far as drivability is concerned, adjustable suspensions are being developed to suit all road types, from urban freeways to off-road surfaces. Further developments for Zero remain top-secret for the time being, but will be disclosed at the end of the year and will be available in 2011.
Spring 2012 will see the Roadster take to the roads.
Just 18 months before we will see the open top version of the Tazzari Zero ready for those star-filled summer nights. Available in Spring 2012, the Tazzari Zero Roadster is perfect for the free-spirited lovers of driving sensations.
Finally, we would like to wish all our readers a great summer break, dreaming of the Zero Roadster!
ABOUT TAZZARI GROUP
Scott O'Neal, COO of Evarco, stated, "As Evarco moves forward to find forward thinking, Future Driven®, dealers in the U.S. & South America we are excited to be working with Tazzari as they develop new products, improve advanced technology & performance. We feel that working with an Italian manufacturer with executive styling & sustainable technology will make our future not only greener, but the envy of the road."
SINO FIBRE COMMUNICATIONS (OTCBB: SFBE)
"Up 33.33% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SFBE.php
Sino Fibre Communications, Inc. operates as a broadband carrier to provide services to the wholesale carrier and service provider segments of the broadband market in the People's Republic of China. The company markets and sells fiber optic backbone services of Sino-Con Telecomm Group., Ltd. (Sino-Con) to foreign telecommunications carriers and corporate users. Sino-Con's fiber optic backbone provides a fiber optic network within China that allows for long distance and local telephone services, Internet services, television services, and wireless LAN services. The company was founded in 1999. It was formerly known as Pacific Rim Solutions, Inc. and changed its name to Sino Fibre Communications, Inc. in 2006. Sino Fibre Communications is based in New York, New York.
October 15 - Sino Fibre Closes Acquisition to Acquire Inner Mongolia Bio-Energy Company
Sino Fibre Communications, Inc. (OTCBB: SFBE) announced that it has closed an acquisition to acquire 50.1% of Europe-China Commercial Union Holdings Ltd "ECL" for US$100 million.
The consideration for the $100 million acquisition was 400 million SFBE shares ($0.25 per share) representing 140 million SFBE newly issued shares (valued at US$35 million) and a promissory note for 260 million SFBE shares (valued at US$65 million). ECL indirectly holds a 70% interest in approximately 70 sq. kilometers of leased land in Inner Mongolia Province, China. The land rights expire on 31 December 2049.
Daniel McKinney, CEO of Sino Fibre, commented on this new business; "This acquisition is a major turning point in the history of our company and propels us into the high growth arena of bio-energy, bio-diesel, wind and solar farms in China. With our large land resource in Inner Mongolia, the company can develop multiple streams of cash flows in this high growth, green sector."
The company will be appointing new management and board of directors, as well as changing the company name to Sinobioenergy.com.
HIGHWAY HOLDINGS LIMITED (NASDAQ: HIHO)
"Up 34.04% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/HIHO.php
Highway Holdings produces a wide variety of high-quality products for blue chip original equipment manufacturers — from simple parts and components to sub-assemblies. It also manufactures finished products, such as light fixtures, LED lights, radio chimes and other electronic products. Highway Holdings is headquartered in Hong Kong, and currently operates with its principal manufacturing facility in Shenzhen and a factory in Wuxi in the People's Republic of China.
October 6 - Highway Holdings Receives Tooling and Product Orders for Mobile Phone Cases
Highway Holdings Limited (Nasdaq: HIHO) announced it has received orders valued at approximately $5.56 million for protective cases for a popular mobile phone from a U.S.-based supplier of these accessories.
The manufacture of protective cases for the initial two-month order has commenced and delivery is expected to be completed within sixty days. Highway Holdings anticipates receiving similar ongoing monthly orders upon achieving full production capacity.
"We are gratified by the confidence of this new customer in our quality and technical capabilities and look forward to developing a long-term business relationship as a key supplier," said Roland Kohl, president and chief executive officer.
He noted that the mobile phone protective cases will be produced by the company's Golden Bright Plastic Manufacturing subsidiary, which was acquired in 2006 and subsequently integrated to further enhance Highway Holdings' manufacturing capabilities.
PHARMATHENE INCORPORATED (AMEX: PIP)
"Up 31.35% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/PIP.php
PharmAthene, Inc., a biodefense company, together with its subsidiaries, engages in the development and commercialization of medical countermeasures against biological and chemical weapons in the United States. Its product candidates include SparVax, a recombinant protective antigen (rPA) anthrax vaccine to protect against inhalation anthrax that has completed one Phase I and two Phase II clinical trials; and Valortim, a human monoclonal antibody to protect against and treat human inhalational anthrax, which has completed Phase I clinical trial. The company’s product candidates also include Protexia, a recombinant enzyme (butyrylcholinesterase), which mimics a natural bioscavenger for the prevention or treatment of nerve agent poisoning by organophosphate compounds, including nerve gases and pesticides. In addition, its product candidates include RypVax, a recombinant plague vaccine comprising separate recombinant F1 (rF1) and V (rV) antigens produced in Escherichia coli, which completed three Phase I human clinical trials; and rPA anthrax vaccine, which does not require refrigeration. The company’s customers include National Institute of Allergy and Infectious Diseases, the U.S. Department of Defense, Biomedical Advanced Research and Development Authority, and the U.S. National Institutes of Health. It has a collaboration agreement with Medarex, Inc. to develop and commercialize Valortim. PharmAthene, Inc. was founded in 2001 and is based in Annapolis, Maryland.
October 14 - PharmAthene Listing Compliance Plan Accepted by the NYSE Amex
PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that based on information provided by PharmAthene in its compliance plan, and discussions with Exchange staff, the NYSE Amex LLC (NYSE Amex) has determined that the Company made a reasonable demonstration of its ability to regain compliance with the NYSE Amex listing requirements and granted PharmAthene an extension until January 26, 2012 to demonstrate its compliance.
Eric I. Richman, PharmAthene's interim Chief Executive Officer, noted, "We are extremely pleased by this decision and optimistic in our ability to satisfy the continued listing standards of the NYSE Amex by the end of the extension period. PharmAthene will be able to continue its listing during this time, subject to periodic reporting regarding progress under the compliance plan and review by the NYSE Amex staff."
On July 26, 2010 the Company had received a letter from the NYSE Amex, stating that it is not in compliance with the continued listing standards specified in Sections 1003(a)(i), (ii) and (iii) of the NYSE Amex Company Guide, because it had stockholders' equity of less than $2.0 million, $4.0 million and $6.0 million and losses from continuing operations and/or net losses in two of its three most recent fiscal years, three of its four most recent fiscal years and its five most recent fiscal years, respectively. PharmAthene submitted a compliance plan on August 25, 2010, addressing how it intends to regain compliance with Sections 1003(a)(i), (ii) and (iii) of the Company Guide by January 26, 2012.
ENCOUNTER TECHNOLOGIES INCORPORATED (OTC: ENTI)
"Up 22.22% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/ENTI.php
Encounter Technologies, Inc. provides end-to-end technology and online marketing services, including design, build, hosting, and online marketing support. We specialize in social media, video technology, and online entertainment web solutions. Encounter Technologies, Inc. (ENTI) utilizes their pre-built applications to provide the platforms in which to base solutions for businesses looking to utilize video technology to increase online collaboration and interaction. Our goal is to provide our clients with the best methods to increase user value and achieve desired business results. Simply put, Encounter Technologies, Inc. transforms ideas into revenues.
October 18 - Encounter Technologies, Inc. Promotion With Vado and Jae Millz Gaining Momentum and Exposure
Photos of Exclusive Music Matrix Video Shoot Released Online
Encounter Technologies, Inc. (OTC: ENTI) reveals behind-the-scenes photos of the exclusive video shoot with rappers Vado and Jae Millz. The Music Matrix team shot custom footage in Harlem and The Bronx for a full-length video and interactive music video promotion to premier on the site. The photos are branded with the Music Matrix name and are now highlighted in the gallery section of the popular web site, http://www.whatspoppin.net. What's Poppin' is an entertainment driven service that showcases the hottest event listings and photo opportunities. It consistently ranks in the top three urban promotion web sites and reaches tens of thousands of loyal, hip hop fans each month.
Music Matrix interactive music video promotions allow premium users to engage with their favorite artists. The promotion for Vado and Jae Millz features the song "Respect the Jux" inspired by the Frank Matthews' novel of the same name. An exclusive video will premiere on MusicMatrix.com followed by a promotion for Matthews' novel. As the hype begins to swirl, the video is expected to go viral and provide tremendous exposure for MusicMatrix.com.
According to industry buzz, Cam'ron's protégé, Vado, is the new generation's heavy hitter with a promising future in the rap game. He is one of the top, underground rappers with a soon-to-be released album, "Slime Flu." Vado's strong following of 33,965 followers on Twitter and 247,161 My Space Views is just the beginning. Vado was first introduced to the game by legendary battle rapper, Jae Millz. Over the past decade, Millz has mastered the mixtape scene and earned a respected name in hip hop. The New York rapper has been performing worldwide with YME and sharing the stage with Lil Wayne, Drake, Nicki Minaj, Young Jeezy, and T-Pain on the "America's Most Wanted" and "I Am Music" tours in front of arena crowds averaging 25 thousand on each stop. Millz is also known for his television cameo on MTV's, "Making the Band" for a freestyle battle with E. Ness garnering more than half a million YouTube views. Millz brings an established fan base to Music Matrix with 2,702,776 profile views and 119,146 friends on Myspace and 130,866 followers on Twitter.
On MusicMatrix.com, users are able to participate in music video editing competitions in order to win both prizes and recognition. Encounter Technologies, Inc. (ENTI) has developed a cutting edge, innovative, and simple to use platform for MusicMatrix.com, which facilitates the video uploading, editing, sharing, and viewing experiences. By creating an environment which rewards both innovation and creativity, users are given the incentive to implement their own unique online marketing campaigns in order to expose a particular artist or song to populations and demographics not typically reached through standard mass campaigns.
CANNABIS SCIENCE INCORPORATED (OTCBB: CBIS)
"Up 7.30% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/CBIS.php
Cannabis Science Inc. is at the forefront of medical marijuana research and development. The company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. It is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
October 12 - Cannabis Science Issues Guidance on Its Progress Toward FDA Investigative New Drug Applications For Clinical Trials and Proposed Dividend Payout for Current Shareholders to Receive a New Class of Common Stock
Cannabis Science, Inc. (OTCBB: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce guidance on its product development and FDA Investigative New Drug Applications for its cannabis clinical trials. The Company is also pleased to announce the proposed dividend payout to current shareholders for a new class of common shares is under review by counsel, and the Company expects to announce the date of shareholder record, the proposed share ratio payments, and attached financing options within the next few days.
Cannabis Science Inc. President & CEO, Dr. Robert Melamede Ph.D., commented, "We are at the beginning stages of our growth curve right now. This is the most exciting time yet for us all in our short history, we see the proposed dividend payout with the proposed new class of common shares as a way to multiply, reward, and increase our investor options and participation. Our operational structure has been increased dramatically by the ever-increasing amount of partnership opportunities. We have seen some impressive results worldwide from cannabis patients, whether they are using medical cannabis in what is considered informal trials or for personal edification. Absurdly, this vast trove of clinical experience has been dismissed as 'anecdotal.' At some point that willful blindness is not only unscientific, it is simply dishonest. However, it has created a great opportunity for us. Cannabis Science is in the strategic planning phase with respect to the enormous amount of positive research and data collection coming from all of this 'real world' experience of thousands of Colorado patients. Consequently, we are forming a well-qualified team of physicians, and this data will be compounded through our RockBrook agreements and later used with respect to the FDA applications and clinical trials. At this point our focus remains on submitting our initial Investigative New Drug Applications to FDA, so we are weighing the options and expect to announce a decision in the near future."
Cannabis Science is implementing its pharmaceutical grade cannabis product development and quality control standardizations through its licensed commercialization developer RockBrook Inc. and is currently negotiating its laboratory quality control standardizations with another group. This will be a large contribution to the body of evidence presented as part of our Investigative New Drug Applications to the FDA for the critical ailments, which we will be pursuing through the FDA regulatory process.
Cannabis Science Inc. Lab Director, Christopher Stubbs, remarked, "The Cannabis Science Lab Division has been compiling pharmaceutical guidance for The Company and its affiliates with respect to horticulture standards and practices, good manufacturing compliance, health and safety profiling of medical cannabis and formulated products, as well as FDA guidance for our long-term goals. We've also been busy generating new scientific partnerships and collaborations in order to meet our needs. As has always been the case, our ultimate aim is to bring multiple levels of cannabis treatment to market, with proper case documentation and organization of viable clinical trials that utilize FDA regulatory guidance and operations transparency. This provides a strong scientific basis for internal use, as well as industry dissemination. With respect to both patient treatment and dosing – utilizing well-characterized, standardized products – the Cannabis Science horticultural method and product formulation model is being implemented in the State of Colorado. Our entry into other medical cannabis states through licensing agreements or partnerships will follow suit in a timely manner, as many organizations will benefit from the application research we have been engaged in."
The following is a prioritized list of potential FDA Investigative New Drug Indications that Cannabis Science is researching:
Pain Management – Cannabis use in pain management has long been documented clinically and anecdotally. A recent Canadian Medical Association publication showed "Our results support the claim that smoked cannabis reduces pain, improves mood and helps sleep"(Ware et al 2010).
The medical cannabis dispensary model has provided a wealth of observational data, with pain patients reporting improved pain management as well as increases in overall quality of life after beginning cannabis therapy. Cannabis Science licensee RockBrook, Inc. works with one of the leading pain management doctors in the State of Colorado, which has led to the selection of a standardized cannabis strain and appropriate methods of ingestion for these patients. This strain and its formulated products will be available for dispensary sale in the next quarter. Because pain management is often associated with Post Traumatic Stress Disorder (PTSD, see below), it is likely that both indications will be targeted with this same formulation in the new drug application.
Last year, MarketResearch.com reported that the "global pain management market generated $46.4 billion sales in 2007, a 12.5% increase over 2006. The most prevalent forms of neuropathic pain in the seven major markets were neuralgia/fibromyalgia and lower back pain, with 16.3m and 15.9m cases respectively during 2008."
Post Traumatic Stress Disorder (PTSD) – Recent peer-reviewed literature, as well as practical applications in foreign markets such as Israel, show that medical cannabis can be extremely effective in the clinical treatment of PTSD and associated symptoms. Cannabis Science has also received clear input from veterans in Colorado that this treatment is safe and effective. Cannabis Science and its colleagues have been assembling a petition to the Colorado Department of Health and Environment to gain acceptance for medical cannabis use for PTSD under the state regulations. Furthermore, The Company is in the planning phase with the CBR International Group, to complete the New Drug Application based on CBIS proprietary methodologies and formulations to treat PTSD safely and effectively. Because the extent of the PTSD problem has only recently been recognized, it is impossible to quantify the market at this point, but it is expected to be very large and its importance transcends whatever the initial estimates may be.
Cancer- Beyond the well known palliative options that cannabis provides for patients suffering from cancer and the side-effects of the standard treatments, there has been a worldwide explosion of scientific studies demonstrating the ability of cannabinoids to kill cancer cells in animals and tissue culture. Additionally, patients have initiated personal experimentation in medical marijuana states. Currently, CBIS is aware of multiple patients involved in a cannabis treatment regimen implemented by the www.PhoenixTearsFoundation.com to reduce the likely hood of cancer progression, improve quality of life through increased sleep and nutrition intake, and possibly spur remission.
It is clear that a standardized, well-profiled, and safe cannabis extract must be used for the treatment of this disease. Our goal is to coordinate clinical partnerships and patient care with our standardized product line in Colorado, and to gather data that supports the use of cannabis extracts for this indication before pursuing a new drug application. Cannabis Science has been actively working with other organizations to meet this need not only on the dispensary level, but also with respect pursuing FDA approval. Cancer drugs tend to be hugely expensive, so it is a multibillion-dollar market, but is not clear how the current market size could be extrapolated into any valuation of cannabis products, which would cost far less.
Influenza- Several cannabinoids have been shown to possess anti-inflammatory properties that could be beneficial in a variety of disease states, including many pro-inflammatory influenza strains such as the avian flu (H1N5). The secondary effects of influenza infection in susceptible populations can be the cause of eventual death from inflammation-induced Adult Respiratory Distress Syndrome (ARDS). In fact, several peer-reviewed publications have focused on the modulation of pulmonary inflammation by cannabinoids in numerous organs after mice were inoculated with highly inflammatory influenza strains (Buchweitz et al 2007). Bringing a drug to market that safely and effectively mitigates these inflammatory consequences could drastically reduce the annual death rates associated with influenza. Cannabis Science is researching possible formulations to achieve this goal in humans.
Asthma- Affecting nearly 300 million people worldwide, its incidence has been on the rise. Historically, cannabis was routinely used for treating asthma. Its bronchial dilating properties are well documented. Modern medical marijuana users have rediscovered its effectiveness for treating this illness. Cannabis Science is currently in the early stage of development with cannabis-based based products to address this need. Local observational trials in Colorado will further guide product development in the near future. Lead Discovery of the UK estimates that the "asthma treatment market is a $15 billion market, driven by an increasing prevalence and yet without a treatment to cure this debilitating disease."